RENTON HOLLINGS 4

4 · ANAPTYSBIO, INC · Filed Apr 22, 2026

Research Summary

AI-generated summary of this filing

Updated Apr 22, 2026

ANAPTYSBIO (ANAB) Director Renton Hollings Receives Option Awards

What Happened

Renton Hollings, a director of AnaptysBio (ANAB), reported multiple derivative transactions on April 20, 2026 consisting of disposals to the issuer and concurrent acquisitions of options (all at $0.00). The reported acquisitions total options covering 107,320 underlying shares (aggregate of the A entries). No cash was paid or received; these entries reflect option adjustments tied to a corporate separation/spin-off.

Key Details

Transaction date: April 20, 2026; Form 4 filed April 22, 2026 (timely).
Transaction type: Derivative adjustments/awards (dispositions to issuer paired with new option grants), price reported $0.00; total underlying shares acquired via options: 107,320.
Shares/position after transaction: The filing reports the newly adjusted option grants; it does not show a cash sale or open-market trade of common stock.
Notable footnotes:
- F1: These adjustments resulted from a pro rata distribution under the Separation and Distribution Agreement with First Tracks — each existing option was split/adjusted into options for First Tracks and for AnaptysBio, producing the reported AnaptysBio option awards.
- F2: Some option(s) are fully vested and exercisable.
- F3: Other option(s) vest 1/12 monthly beginning Feb 6, 2026, subject to continued service.

Context

This filing documents option adjustments due to a corporate separation, not an open-market buy or sale. Such administrative option reallocations are common after spin-offs and do not necessarily signal the insider buying or selling stock for personal investment reasons. For retail investors, purchases or sales of common stock are typically more indicative of insider sentiment than post-transaction option adjustments.

Insider Transaction Report

Form 4

Period: 2026-04-20

ANAPTYSBIO, INCANAB

RENTON HOLLINGS

Director

Transactions

Disposition to Issuer
Stock Option (right to buy)
[F1][F2]
2026-04-20−15,000→ 15,000 total
Exercise: $24.60Exp: 2027-02-23→ Common Stock (15,000 underlying)
Award
Stock Option (right to buy)
[F1][F2]
2026-04-20+15,000→ 15,000 total
Exercise: $18.03Exp: 2027-02-23→ Common Stock (15,000 underlying)
Disposition to Issuer
Stock Option (right to buy)
[F1][F2]
2026-04-20−6,000→ 6,000 total
Exercise: $104.81Exp: 2028-02-01→ Common Stock (6,000 underlying)
Award
Stock Option (right to buy)
[F1][F2]
2026-04-20+6,000→ 6,000 total
Exercise: $76.79Exp: 2028-02-01→ Common Stock (6,000 underlying)
Disposition to Issuer
Stock Option (right to buy)
[F1][F2]
2026-04-20−6,000→ 6,000 total
Exercise: $68.88Exp: 2029-02-07→ Common Stock (6,000 underlying)
Award
Stock Option (right to buy)
[F1][F2]
2026-04-20+6,000→ 6,000 total
Exercise: $50.47Exp: 2029-02-07→ Common Stock (6,000 underlying)
Disposition to Issuer
Stock Option (right to buy)
[F1][F2]
2026-04-20−11,000→ 11,000 total
Exercise: $16.56Exp: 2030-02-11→ Common Stock (11,000 underlying)
Award
Stock Option (right to buy)
[F1][F2]
2026-04-20+11,000→ 11,000 total
Exercise: $12.14Exp: 2030-02-11→ Common Stock (11,000 underlying)
Disposition to Issuer
Stock Option (right to buy)
[F1][F2]
2026-04-20−11,000→ 11,000 total
Exercise: $29.70Exp: 2031-02-09→ Common Stock (11,000 underlying)
Award
Stock Option (right to buy)
[F1][F2]
2026-04-20+11,000→ 11,000 total
Exercise: $21.76Exp: 2031-02-09→ Common Stock (11,000 underlying)
Disposition to Issuer
Stock Option (right to buy)
[F1][F2]
2026-04-20−9,200→ 9,200 total
Exercise: $30.44Exp: 2032-02-09→ Common Stock (9,200 underlying)
Award
Stock Option (right to buy)
[F1][F2]
2026-04-20+9,200→ 9,200 total
Exercise: $22.13Exp: 2032-02-09→ Common Stock (9,200 underlying)
Disposition to Issuer
Stock Option (right to buy)
[F1][F2]
2026-04-20−10,600→ 10,600 total
Exercise: $23.23Exp: 2033-01-05→ Common Stock (10,600 underlying)
Award
Stock Option (right to buy)
[F1][F2]
2026-04-20+10,600→ 10,600 total
Exercise: $17.02Exp: 2033-01-05→ Common Stock (10,600 underlying)
Disposition to Issuer
Stock Option (right to buy)
[F1][F2]
2026-04-20−16,510→ 16,510 total
Exercise: $21.19Exp: 2034-01-02→ Common Stock (16,510 underlying)
Award
Stock Option (right to buy)
[F1][F2]
2026-04-20+16,510→ 16,510 total
Exercise: $15.53Exp: 2034-01-02→ Common Stock (16,510 underlying)
Disposition to Issuer
Stock Option (right to buy)
[F1][F2]
2026-04-20−16,510→ 16,510 total
Exercise: $14.83Exp: 2035-01-06→ Common Stock (16,510 underlying)
Award
Stock Option (right to buy)
[F1][F2]
2026-04-20+16,510→ 16,510 total
Exercise: $10.87Exp: 2035-01-06→ Common Stock (16,510 underlying)
Disposition to Issuer
Stock Option (right to buy)
[F1][F3]
2026-04-20−5,500→ 5,500 total
Exercise: $43.91Exp: 2036-01-06→ Common Stock (5,500 underlying)
Award
Stock Option (right to buy)
[F1][F3]
2026-04-20+5,500→ 5,500 total
Exercise: $32.17Exp: 2036-01-06→ Common Stock (5,500 underlying)

Footnotes (3)

[F1]Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement.
[F2]The stock option is fully vested and exercisable.
[F3]The stock option vests as to 1/12 of the total shares monthly commencing on February 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Signature

/s/ Dan Faga, Attorney-in-Fact|2026-04-22

Documents

1 file

4
form4-04222026_100427.xmlPrimary